PT  - JOURNAL ARTICLE
AU  - O’Halloran, Jane A.
AU  - Kedar, Eyal
AU  - Anstrom, Kevin J.
AU  - McCarthy, Matthew W.
AU  - Ko, Emily R.
AU  - Nunez, Patricia Segura
AU  - Boucher, Cynthia
AU  - Smith, P. Brian
AU  - Panettieri, Reynold A.
AU  - de Tai, Sabina Mendivil Tuchia
AU  - Maillo, Martin
AU  - Khan, Akram
AU  - Mena Lora, Alfredo J.
AU  - Salathe, Matthias
AU  - Capo, Gerardo
AU  - Gonzalez, Daniel Rodríguez
AU  - Patterson, Thomas F
AU  - Palma, Christopher
AU  - Ariza, Horacio
AU  - Lima, Maria Patelli
AU  - Lachiewicz, Anne M.
AU  - Blamoun, John
AU  - Nannini, Esteban C.
AU  - Sprinz, Eduardo
AU  - Mykietiuk, Analia
AU  - Alicic, Radica
AU  - Rauseo, Adriana M.
AU  - Wolfe, Cameron R.
AU  - Witting, Britta
AU  - Benjamin, Daniel K.
AU  - McNulty, Steven E.
AU  - Zakroysky, Pearl
AU  - Halabi, Susan
AU  - Butler, Sandra
AU  - Atkinson, Jane
AU  - Adam, Stacey J.
AU  - Melsheimer, Richard
AU  - Chang, Soju
AU  - LaVange, Lisa
AU  - Proschan, Michael
AU  - Bozzette, Samuel A.
AU  - Powderly, William G.
AU - ACTIV-1 IM study group members
TI  - Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19
AID  - 10.1101/2022.09.22.22280245
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.09.22.22280245
4099  - http://medrxiv.org/content/early/2022/09/26/2022.09.22.22280245.short
4100  - http://medrxiv.org/content/early/2022/09/26/2022.09.22.22280245.full
AB  - Background Immune dysregulation contributes to poorer outcomes in severe Covid-19. Immunomodulators targeting various pathways have improved outcomes. We investigated whether infliximab provides benefit over standard of care.Methods We conducted a master protocol investigating immunomodulators for potential benefit in treatment of participants hospitalized with Covid-19 pneumonia. We report results for infliximab (single dose infusion) versus shared placebo both with standard of care. Primary outcome was time to recovery by day 29 (28 days after randomization). Key secondary endpoints included 14-day clinical status and 28-day mortality.Results A total of 1033 participants received study drug (517 infliximab, 516 placebo). Mean age was 54.8 years, 60.3% were male, 48.6% Hispanic or Latino, and 14% Black. No statistically significant difference in the primary endpoint was seen with infliximab compared with placebo (recovery rate ratio 1.13, 95% CI 0.99–1.29; p=0.063). Median (IQR) time to recovery was 8 days (7, 9) for infliximab and 9 days (8, 10) for placebo. Participants assigned to infliximab were more likely to have an improved clinical status at day 14 (OR 1.32, 95% CI 1.05–1.66). Twenty-eight-day mortality was 10.1% with infliximab versus 14.5% with placebo, with 41% lower odds of dying in those receiving infliximab (OR 0.59, 95% CI 0.39–0.90). No differences in risk of serious adverse events including secondary infections.Conclusions Infliximab did not demonstrate statistically significant improvement in time to recovery. It was associated with improved 14-day clinical status and substantial reduction in 28- day mortality compared with standard of care.Trial registration ClinicalTrials.gov (NCT04593940).Competing Interest StatementThis information is being collected.Clinical TrialNCT04593940Funding StatementThis project has been funded with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under contract number HHSO100201400002I/75A50120F33002. The findings and conclusions in this publication are those of the authors and do not necessarily represent the views of the Department of Health and Human Services or its components. Janssen provided infliximab for use in this trial but did not provide any financial support. Gilead Sciences provided remdesivir for use in this trial but did not provide any financial support. Employees of Janssen and Gilead Sciences participated in discussions about protocol development and in weekly protocol team calls. The final trial protocol was developed by the protocol chair, Dr. William Powderly, the IND sponsor Dr. Daniel K. Benjamin, Jr, and a protocol development committee including representatives from the National Center for Advancing Translational Sciences (NCATS). NCATS had a collaborative role in the trial design, management, interpretation of the data and the preparation of the manuscript along with the protocol chair, the study statisticians and the study writing group. Infrastructure support and resources for research reported in this publication were provided in part by NCATS of the National Institutes of Health under award number(s):UL1TR002345 to Washington University in St. Louis; the Duke University-Vanderbilt University Medical Center Trial Innovation Center (U24TR001608) (NCATS, Trial Innovation Network).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:WCG IRB gave ethical approval for this work in the US for all sites, with the exception of one site that received approval from the Mid-Michigan IRB of the MyMichigan Medical Center. The following ethics committees gave approval in Argentina: Fundacion Medica del Litoral (FUMELIT), Comite de etica en investigacion del sanatorio Britanico, CEDIMP-Comite de Etica Instituto Medico Platense, Comite de Etica en Investigacion del Hospital Gral de Agudos J. M. Ramos Mejia, Comite de etica e investigacion clinica (CEIC), Sanatorio Allende, Comite de Etica en Investigacion (CIEIS) del Nino y del Adulto, Comite de Etica en Investigacion con Seres Humanos del Hospital Interzonal General Dr. Jose Penna. The following ethics committees gave approval in Brazil: Comite de Etica em Pesquisa da Irmandade da Santa Casa de Misericordia de Porto Alegre, Comite de Etica da Associacao dos Funcionarios Publicos do RS-Hospital Ernesto Dornelles, Comite de Etica em Pesquisa do Hospital de Clinicas de Porto Alegre, Comite de Etica em Pesquisa em Seres Humanos da Pontificia Universidade Catolica de Campinas PUC Campinas, Comite de Etica em Pesquisa do Instituto DOr de Pesquisa e Ensino-IDOR, Comite de Etica em Pesquisa do Hospital Felicio Rocho, Comite de Etica em Pesquisa do Hospital 9 de Julho. The following ethics committees gave approval in Mexico: Nuevo Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Hospital Universitario Dr. Jose Eleuterio Gonzalez, Centro Medico Nacional Siglo XXI (Coordinacion de Investigacion en Salud), Hospital Civil de Guadalajara Fray Antonio Alcalde. The following ethic committees gave approval for all sites in Peru: Comite Nacional Transitorio de Etica e Investigacion (CNTEI). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIt is expected that the partial de-identified patient dataset will be made available via the ACTT Trial Database at NIAID - Access Clinical Data @ NIAID beginning 6 months after publication of the primary results and for 5 years following article publication.